Biotech | May 19, 2026
NunaBio secures £6.5 million to scale DNA manufacturing platform
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The company says the platform offers improved manufacturability and functional advantages
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Subscribe To Our Newsletter & Stay Updated
